The Effect of Vitamin Therapy on the Progression of Corona Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women

Diabetes Care

Volumn 27, Issue 4, 2004, Pages 925-930

  Levy, Andrew P ^a   Friedenberg, Paula ^b   Lotan, Rachel ^a   Ouyang, Pamela ^c   Tripputi, Mark ^b   Higginson, Lyall ^d   Cobb, Frederick R ^e   Tardif, Jean Claude ^f   Bittner, Vera ^g   Howard, Barbara V ^h  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e DUKE UNIVERSITY   (United States)

^f MONTREAL HEART INSTITUTE   (Canada)

^g University of Alabama at Birmingham   (United States)

^h MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CONJUGATED ESTROGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; VITAMIN;

ADULT; AGED; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; VITAMIN SUPPLEMENTATION;

AGED; ANTIOXIDANTS; ASCORBIC ACID; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HAPTOGLOBINS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; PROSPECTIVE STUDIES; VITAMIN E;

EID: 12144291640     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.4.925     Document Type: Article

References (33)

1. Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105:2107-2111, 2002
2. Podrez EA, Adu-Soud HM, Hazen SL: Myeloperoxidase generated oxidants and atherosclerosis. Free Radic Biol Med 28: 1717-1725, 2000
3. Chisolm GM, Steinberg D: The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815-1826, 2000
4. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao YS: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N, N′-diphenyl-phenylenediamine. J Clin Invest 89:1885-1891, 1992
5. Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 84:7725-7729, 1987
6. Diaz MN, Frei B, Vita JA, Keaney JF: Antioxidants and atherosclerotic heart disease. N Engl J Med 337:408-416, 1997
7. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S: The effect of probucol on femoral atheroslcerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74:875-883,1994
8. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I, Walldius G: Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. Arterioscler Thromb Vase Biol 15:1049-1056, 1995
9. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA 288:2432-2440, 2002
10. Waters DD: Estrogen and unstable angina: another bump for the bandwagon. J Am Coll Cardiol 39:238-240, 2002
11. Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A: Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol 22:1535-1546, 2002
12. Lynch SR, Cook JD: Interaction of vitamin C and iron. Ann N Y Acad Sci 355:32-44, 1980
13. McLaran CJ, Bett JHN, Nye JA, Halliday JW: Congestive cardiomyopathy and hemochromotosis-rapid progression possibly accelerated by excessive ingestion of ascorbic acid. Aust N Z J Med 12:187-188, 1982
14. Herbert V, Shaw S, Jayatilleke E: Vitamin C-driven free radical generation from iron. J Nutr 126:1213S-1220S, 1996
15. Rehman A, Collis CS, Yang M, Kelly M, Diplock AT, Halliwell B, Rice Evans C: The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem Biophys Res Commun 246:293-298, 1998
16. Proteggente AR, Rehman A, Halliwell B, Rice Evans CA: Potential problems of ascorbate and iron supplementation: prooxidant effect in vivo? Biochem Biophys Res Commun 277:535-540, 2000
17. Nappi AJ, Vass E: Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid and selected catechols. Biochim Biophys Acta 1336:295-302, 1997
18. Almaas R, Rootwelt T, Oyasaeter S, Saugstad OD: Ascorbic acid enhances hydroxyl radical formation in iron-fortified infant cereals and infant formulas. Eur J Ped 156:488-492, 1997
19. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP: Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98:3693-3698, 2001
20. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92:1193-1200, 2003
21. Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over and point mutation. Adv Hum Genet 12:189-261, 1982
22. Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589-1600, 1996
23. Bernard D, Christophe A, Delanghe J, Langlois M, DeBuyzere M, Comhaire F: The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Red Rep 8:41-46, 2003
24. Hochberg I, Roguin A, Nikolsky E, Chanderaskekhar PV, Cohen S, Levy AP: Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 161:441-446, 200
25. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, Kastrati A: Genotyping of common haptoglobin polymorphism Hp1/2 based on the polymerase chain reaction. Clin Chem 277:13635-13640, 2002
26. Hartl D: A Primer of Population Genetics. 2nd ed. Sunderland, MA, Sinauer, 1988
27. Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, DeBuyzere ML, Bernard DR, Neels HM, Delanghe JR: The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem 46:1619-1625, 2000
28. Langlois MR, Delanghe JR, DeBuyzere ML, Bernard DR, Ouyang J: Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 66:606-610, 1997
29. Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010-1014, 1994
30. Mowri HO, Frei B, Keaney JF: Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radic Biol Med 29:814-824, 2000
31. Waters D, Craven TE, Lesperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 87: 1067-1075, 1993
32. The Heart Outcomes Prevention Evaluation Study Investigators: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342: 154-160, 2000
33. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant supplementation in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360:23-33, 2002